Global Seasonal Affective Disorder Therapeutics Market Growth, Size, Trends Analysis - By Treatment Type, By Disorder Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

PUBLISHED: October 13, 2025

PAGES: 259 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global Seasonal Affective Disorder Therapeutics Market Introduction and Overview

According to SPER market research, 'Global Seasonal Affective Disorder Therapeutics Market Size- By Treatment Type, By Diagnosis Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' states that the Global Seasonal Affective Disorder Therapeutics Market is predicted to reach 1338.53 million by 2034 with a CAGR of 4.98%.

Seasonal Affective Disorder (SAD) is a type of depression that occurs during specific seasons, most notably fall and winter, when natural sunlight is reduced. Light treatment, antidepressant medicines, psychotherapy, and lifestyle changes are all used to treat SAD and improve mood and energy levels. The healthcare and mental health industries are increasingly focusing on creative and patient-friendly techniques to improve treatment accessibility and effectiveness.

Restraints: Despite rising demand, various barriers prevent the widespread use of Seasonal Affective Disorder treatments. Side effects and black-box warnings on antidepressants frequently reduce patient adherence, lowering long-term effectiveness. Low awareness and underdiagnosis in low- and middle-income countries impede prompt treatment access. Furthermore, payor restrictions for off-label psychedelic or ketamine-based clinics limit the expansion of alternate therapy pathways. Another issue comes with LED light boxes, where rare-earth element supply issues jeopardize production stability and availability.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Treatment Type, By Disorder Type, By End User

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered AbbVie, Amen Clinics, Bausch Health Companies, Cleveland Clinic, Eli Lilly and Company, GlaxoSmithKline, Henry Schein, Johnson & Johnson (Janssen Pharmaceuticals), Mayo Clinic, Novartis.

Global Seasonal Affective Disorder Therapeutics Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Seasonal Affective Disorder Therapeutics Market is segmented as; Medications, Therapy.

By Disorder Type: Based on the Disorder Type, Global Seasonal Affective Disorder Therapeutics Market is segmented as; Fall & winter SAD, Spring & summer SAD.

By End User: Based on the End User, Global Seasonal Affective Disorder Therapeutics Market is segmented as; Hospitals, Specialty clinics, Homecare setting, Other end user.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25317

1.Introduction

1.1.Scope of the report
1.2.Market segment analysis

2.Research Methodology

2.1.Research data source
- 2.1.1.Secondary Data
- 2.1.2.Primary Data
- 2.1.3.SPERs internal database
- 2.1.4.Premium insight from KOLs
2.2.Market size estimation
- 2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

4.1.Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1.Drivers
- 4.1.2.Restraints
- 4.1.3.Opportunities
- 4.1.4.Challenges

5.Market variable and outlook

5.1.SWOT Analysis
- 5.1.1.Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
5.2.PESTEL Analysis
- 5.2.1.Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4.Technological Landscape
- 5.2.5.Environmental Landscape
- 5.2.6.Legal Landscape
5.3.PORTERs Five Forces
- 5.3.1.Bargaining power of suppliers
- 5.3.2.Bargaining power of buyers
- 5.3.3.Threat of Substitute
- 5.3.4.Threat of new entrant
- 5.3.5.Competitive rivalry
5.4.Heat Map Analysis

6.Competitive Landscape

6.1.Global Seasonal Affective Disorder Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Seasonal Affective Disorder Therapeutics Market

7.Global Seasonal Affective Disorder Therapeutics Market, By Treatment Type (USD Million) 2021-2034

7.1.Medication
- 7.1.1.Selective serotonin reuptake inhibitors (SSRI)
- 7.1.2.Norepinephrine-dopamine reuptake inhibitor (NDRI)
- 7.1.3.Monoamine oxidase inhibitor (MAOI)
- 7.1.4.Other drug types
7.2.Therapy
- 7.2.1.Light therapy
- 7.2.2.Psychotherapy

8.Global Seasonal Affective Disorder Therapeutics Market, By Disorder Type (USD Million) 2021-2034

8.1.Fall & winter SAD
8.2.Spring & summer SAD

9.Global Seasonal Affective Disorder Therapeutics Market, By End User (USD Million) 2021-2034

9.1.Hospitals
9.2.Specialty clinics
9.3.Homecare setting
9.4.Other end use

10.Global Seasonal Affective Disorder Therapeutics Market, (USD Million) 2021-2034

10.1.Global Seasonal Affective Disorder Therapeutics Market Size and Market Share

11.Global Seasonal Affective Disorder Therapeutics Market, By Region, (USD Million) 2021-2034

11.1.Asia-Pacific
- 11.1.1.Australia
- 11.1.2.China
- 11.1.3.India
- 11.1.4.Japan
- 11.1.5.South Korea
- 11.1.6.Rest of Asia-Pacific
11.2.Europe
- 11.2.1.France
- 11.2.2.Germany
- 11.2.3.Italy
- 11.2.4.Spain
- 11.2.5.United Kingdom
- 11.2.6.Rest of Europe
11.3.Middle East and Africa
- 11.3.1.Kingdom of Saudi Arabia
- 11.3.2.United Arab Emirates
- 11.3.3.Qatar
- 11.3.4.South Africa
- 11.3.5.Egypt
- 11.3.6.Morocco
- 11.3.7.Nigeria
- 11.3.8.Rest of Middle-East and Africa
11.4.North America
- 11.4.1.Canada
- 11.4.2.Mexico
- 11.4.3.United States
11.5.Latin America
- 11.5.1.Argentina
- 11.5.2.Brazil
- 11.5.3.Rest of Latin America

12.Company Profile

12.1.AbbVie
- 12.1.1.Company details
- 12.1.2.Financial outlook
- 12.1.3.Product summary
- 12.1.4.Recent developments
12.2.Amen Clinics
- 12.2.1.Company details
- 12.2.2.Financial outlook
- 12.2.3.Product summary
- 12.2.4.Recent developments
12.3.Bausch Health Companies
- 12.3.1.Company details
- 12.3.2.Financial outlook
- 12.3.3.Product summary
- 12.3.4.Recent developments
12.4.Cleveland Clinic
- 12.4.1.Company details
- 12.4.2.Financial outlook
- 12.4.3.Product summary
- 12.4.4.Recent developments
12.5.Eli Lilly and Company
- 12.5.1.Company details
- 12.5.2.Financial outlook
- 12.5.3.Product summary
- 12.5.4.Recent developments
12.6.GlaxoSmithKlinz
- 12.6.1.Company details
- 12.6.2.Financial outlook
- 12.6.3.Product summary
- 12.6.4.Recent developments
12.7.Henry Schein
- 12.7.1.Company details
- 12.7.2.Financial outlook
- 12.7.3.Product summary
- 12.7.4.Recent developments
12.8.Johnson & Johnson (Janssen Pharmaceuticals)
- 12.8.1.Company details
- 12.8.2.Financial outlook
- 12.8.3.Product summary
- 12.8.4.Recent developments
12.9.Mayo Clinic
- 12.9.1.Company details
- 12.9.2.Financial outlook
- 12.9.3.Product summary
- 12.9.4.Recent developments
12.10.Novartis
- 12.10.1.Company details
- 12.10.2.Financial outlook
- 12.10.3.Product summary
- 12.10.4.Recent developments
12.11.Others